A longevity clinic chain is franchising stem-cell and IV therapy into six new markets — the evidence base is not expanding with it

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Longevity medicine is scaling like a franchise business, because it is one. The question this announcement raises is not whether the clinics will open — the dates are set — but what level of proof is being franchised along with the brand.

What exactly was announced?

Per the company's November 3, 2026 announcement: six new franchise and corporate locations joining existing clinics in Austin, Dallas and Palm Beach Gardens. Palm Desert and Park City are expected to open this month (November 2026); San Antonio in January 2027; Houston and Kansas City begin construction in December 2026; Mexico City, the first international location, is expected in early 2027. The Park City site follows Humanaut's acquisition of Docere Clinics and will operate as its first Stem Cell Center of Excellence under Dr. Harry Adelson's clinical team, offering orthopedic and spine stem-cell procedures, stem-cell IV infusions, hyperbaric oxygen therapy and IV therapies; the company notes it also offers stem-cell therapy at its other locations, including procedures for the spine, knee, shoulder, hip, elbow, wrist and other joints.

Where do mitochondria come in?

Mostly in the marketing grammar of the category. Regenerative and longevity clinics commonly frame their services — stem cells, IV nutrient infusions, hyperbaric oxygen — in the language of cellular repair and mitochondrial energy. Readers should know what the record shows for the specific offerings named here: stem-cell interventions have established roles in a narrow set of blood and immune disorders, while stem-cell IV infusions marketed for general rejuvenation or joint and spine conditions have no established efficacy evidence and no measured mitochondrial outcomes; IV nutrient therapy's mitochondrial claims rest largely on mechanism and anecdote rather than controlled trials; hyperbaric oxygen has established uses (such as specific wound and decompression indications) distinct from longevity use. The announcement itself cites no studies, no outcomes data and no mitochondrial measurement of any kind.

What should a prospective customer ask?

Three questions separate a clinic visit from a leap of faith. First: for my specific condition, what controlled-trial evidence supports this exact intervention — not the category, the intervention? Second: is this use within the product's approved indications, or off-label and experimental — and who bears the risk and cost if it does nothing? Third: what outcome will we measure, when, and what result would make us stop? A chain growing from three clinics to nine across two countries is evidence of demand. Demand is not evidence of efficacy, and the two should never be priced the same.

Where the evidence stands

• Established: The business facts: the six locations, timelines, the Docere Clinics acquisition and the Park City service list are as stated in the company's November 3, 2026 announcement.
• Contested: The value of franchised regenerative services. Proponents point to patient reports and early studies; regulators and independent reviewers note the gap between marketed uses and controlled-trial support.
• Absent: Established efficacy evidence — and any mitochondrial outcome data — for stem-cell IV infusions and longevity IV therapy as marketed for general rejuvenation.